These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27297910)

  • 1. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis.
    Tursi A; Allegretta L; Della Valle N; Hadad Y; Penna A; Pranzo G; Ricciardelli C; Paiano P; Picchio M
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):e61-e63. PubMed ID: 27297910
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy.
    Tursi A; Della Valle N; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Aliment Pharmacol Ther; 2016 Mar; 43(5):657-8. PubMed ID: 26843348
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
    Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
    Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with golimumab in clinical practice for ulcerative colitis.
    Castro-Laria L; Argüelles-Arias F; García-Sánchez V; Benítez JM; Fernández-Pérez R; Trapero-Fernández AM; Gallardo-Sánchez F; Pallarés-Manrique H; Gómez-García M; Cabello-Tapia MJ; Talavera-Fabuel A; Bejarano-García A; Leo-Carnerero E; Hernández-Martínez Á; Caunedo-Álvarez Á; Herrerías-Gutiérrez JM
    Rev Esp Enferm Dig; 2016 Mar; 108(3):129-32. PubMed ID: 26786341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of ulcerative colitis.
    Dalal L
    J Assoc Physicians India; 2007 Sep; 55():635-40. PubMed ID: 18051737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golimumab-associated persistent erythema multiforme in a patient with ulcerative colitis in full remission.
    Badavanis G; Pasmatzi E; Kapranos N; Monastirli A; Tsambaos D
    Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golimumab for moderate to severe ulcerative colitis.
    Strik AS; Berends SE; Mathôt RA; D'Haens GR; Löwenberg M
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):401-406. PubMed ID: 28276288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab: clinical update on its use for ulcerative colitis.
    Gilardi D; Fiorino G; Allocca M; Bravatà I; Danese S
    Drugs Today (Barc); 2015 Mar; 51(3):171-84. PubMed ID: 25876561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.
    Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A
    J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TNF-alpha antibody treatment and remission induction in ulcerative colitis: a review of a Cochrane review].
    Bjerrum JT; Munck LC; Krogh-Madsen M; Nielsen OH
    Ugeskr Laeger; 2007 Feb; 169(9):792-5. PubMed ID: 17355842
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Detrez I; Gils A
    J Crohns Colitis; 2017 Jan; 11(1):1-2. PubMed ID: 27481879
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    PLoS One; 2016; 11(8):e0160444. PubMed ID: 27494322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.